Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia Supported by the National Institute for Health Research and Cancer Research UK funding to the Barts ...
CHICAGO -- Adding investigational capivasertib to fulvestrant extended survival in patients with aromatase inhibitor-resistant estrogen receptor (ER)-positive, HER2-negative advanced breast cancer, ...
The FDA Just Approved a New Drug for an Aggressive Form of Prostate Cancer — and It Targets the Disease in a Way No Approved ...
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by AstraZeneca for Truqap ™ (capivasertib). Truqap ™ is an ...
Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). This is an ASCO Meeting Abstract from the 2019 ...
The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has ...
AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled ...
In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled ...
The FDA has approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for men with phosphatase and tensin homolog (PTEN)-deficient metastatic androgen pathway ...
USA, New York State, New York City Adding capivasertib to treatment with fulvestrant improved progression-free survival in aromatase inhibitor-resistant, HR+, HER2- advanced breast cancer. Adding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results